Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada
|
|
- Kelley Richardson
- 8 years ago
- Views:
Transcription
1 Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada April 2009 Jack V. Tu, MD PhD FRCPC CANADA RESEARCH CHAIR IN HEALTH SERVICES RESEARCH Institute for Clinical Evaluative Sciences (ICES) Division of Cardiology, Schulich Heart Centre Sunnybrook Health Sciences Centre University of Toronto
2 Presenter Disclosure Information Jack V. Tu Using Clinical Registries To Create Evidencebased Health Care Policy FINANCIAL DISCLOSURE: NONE UNLABELED/UNAPPROVED USES DISCLOSURE: None
3 Outline Canadian healthcare system and clinical registries Examples of using clinical registries to create evidence-based health care policy in Ontario Challenges / conclusions
4
5
6 Canadian Health Care System - Overview Universal health care system = single payer model Health care is a provincial responsibility Physician and hospital services All citizens are covered for all medically necessary services (no co-payments or deductibles) Outpatient medications Elderly aged >65 are covered (with small co-payments) Non-elderly: private coverage or direct payment Funded predominantly through general tax revenues Per capita annual health expenditures - $3,000 US (10% of GDP, 2007)
7 Examples of clinical registries in Canada A number of well established, population-based clinical registries exist in Canada Cardiac Care Network (CCN) of Ontario Registry of the Canadian Stroke Network (RCSN) APPROACH cardiac procedures database ICONS ACS registry in Nova Scotia
8 Strengths of Canadian clinical registries Ability to cover 100% of the population (no selection biases) Ability to link to other population-based administrative databases via common unique identifier (via encrypted health card numbers) Regionalization of advanced tertiary cardiac services to a limited number of centers (PCI, CABG, etc.) Privacy legislation and officials that support clinical registries/research Governmental funding for several clinical registries
9 Linkable administrative databases in Canada Hospitalization and Emergency Room databases Drug Benefit databases Physician Claims databases Vital Statistics databases Laboratory databases
10 Advantages of working with policy makers on clinical registries Can mandate participation of providers/hospitals Provide access to publicly-funded administrative databases May provide stable long-term government funding vs. short-term, smaller peer-reviewed grant funding Provides researchers with academic freedom and independence in publishing results Interaction with policy makers allows researchers to understand the questions of interest to policy makers and design clinical registries to answer these questions
11 Examples of Clinical Registries that have led to evidence-based policy decisions in Ontario Privacy legislation and the Registry of the Canadian Stroke Network (RCSN) Drug Eluting Stent (DES) policy and the Cardiac Care Network (CCN) of Ontario
12 Tu et al. NEJM 350: , 2004
13 Registry of the Canadian Stroke Network Purpose: Monitor and improve the quality of stroke care in Canada Began in 2001, as a prospective registry involving 20 regional stroke centers in 8 provinces Designed in part to support evaluation of a government-funded $30 million Ontario stroke strategy Regional stroke centers (focus on tpa) Privacy landscape in Canada in a state of rapid flux Informed consent model selected due to Concern that patient consent would become mandatory per pending legislation Plan to contact patients following hospital discharge re quality of life Plan to share aggregate analyses of registry data with commercial organizations developing medications or aids for daily living
14 Registry of the Canadian Stroke Network Neurology research nurses at each site were trained to obtain informed consent, collect chart-based data and to conduct follow up interviews Study enrollment and data collection were hampered due to Difficulty obtaining consent from eligible patients Lengthy consent process (median=40 minutes) led to reduced time available for data collection Overall only 39% of eligible patients consented to participate in Phase 1 of the registry Despite a re-launching effort beginning in mid-2002, participation rate remained low at 51% in Phase 2
15 Reasons for non-participation Tu et al. NEJM 350: , 2004
16 Selection bias in enrolled participants Tu et al. NEJM 350: , 2004
17 Ontario PHIPA Privacy legislation (2004) The Personal Health Information Protection and Electronic Documents Act, subsequently passed in 2004, legislated Prescribed registries RCSN, CCN, similar to the cancer registry Prescribed entities ICES (high security data institutes where clinical and administrative databases can be linked together for research purposes) Information can be collected without informed consent, provided adequate privacy safeguards approved by the Privacy Commissioner were in place Patient notification was required (e.g. brochures, posters, web sites, etc)
18 N Engl J Med 2007; 357:
19 Drug Eluting Stent (DES) Policy in Ontario Background Drug-eluting stents (DES) introduced in Canada in 2002/2003 Cost ~ $3000 per stent vs. $600 for a bare-metal stent (BMS) A limited # of clinical trials suggested DES were most-effective in reducing restenosis in high-risk patients (e.g., diabetes, long lesions, small vessels) Ministry of Health (MOH) agreed to selectively fund DES for ~ 40% of all PCI cases Conditional upon all Ontario PCI hospitals participating in a provincial PCI stent clinical registry MOH commissioned a real-world analyses of cost and clinical effectiveness of DES to assist in setting provincial funding policy A collaborative initiative between Program for Assessment of Technologies in Health (PATH), Institute for Clinical Evaluative Sciences (ICES) and the Cardiac Care Network (CCN) of Ontario
20 Field Evaluation Studies OHTAC (Ontario Health Technology Assessment Committee) Funding for new devices conditional upon additional data collection (e.g. registry, RCT) Develop additional evidence to help policy makers make evidence-based resource allocation decisions Similar to concept of Coverage with Evidence Development (CED) CMS
21 DES Study Data Sources Cardiac Care Network of Ontario maintains a population-based clinical registry for all PCI procedures Demographics, clinical characteristics, comorbid conditions Stent type / size / length Lesion location / severity Linked to various administrative data sources to determine additional comorbidities and patient outcomes
22 Inclusion criteria DES Study Sample Began with 13,353 patients who underwent PCI in Ontario from Dec 1, 2003 and March 31, 2005 to provide at least 1 year of followup A propensity-score matched set (on 21 baseline characteristics) of 3751 pairs of patients used for the primary analysis
23 TARGET VESSEL REVASCULARIZATION (TVR) RATES TVR-free Survival (%) DES BMS p< % 10.7% Time following Index PCI (years) No. at Risk DES BMS
24 N Engl J Med 2007; 357:
25 N Engl J Med 2007; 357:
26 DES Study Conclusions Drug-eluting stents were most effective in reducing target-vessel revascularization among high-risk patients 2 or more risk factors (diabetes, small vessels, long lesions) No increased rate of death or myocardial infarction Data this study provided important evidence to support the government s long-term selective funding policy for DES
27 Challenges in using clinical registries to create evidence-based health care policies Competing timelines Policy makers may need data within days to weeks whereas research can take months to years Need to maintain ongoing relationships with policy makers who may frequently change due to elections, etc. Ongoing need to demonstrate utility and value of funding clinical registries vs. simply funding more health services Lobbying from stakeholders who may be adversely affected by research results
28 Conclusions Researchers and policy makers can work together to create evidence-based health care policies using clinical registries Policy makers can identify the key questions and provide funding to answer them Researchers can design and publish rigorous scientific studies to answer the questions confronting policy makers Collaboration between policy makers and researcher can help improve heath policy and the health care system
29 Thank you
PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationCopenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,
More informationUniversity of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial
Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan
More informationUsing 'Big Data' to Estimate Benefits and Harms of Healthcare Interventions
Using 'Big Data' to Estimate Benefits and Harms of Healthcare Interventions Experience with ICES and CNODES DAVID HENRY, PROFESSOR OF HEALTH SYSTEMS DATA, UNIVERSITY OF TORONTO, SENIOR SCIENTIST, INSTITUTE
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.1056/NEJMSA1107913 Niteesh K. Choudhry, MD, PhD, 1 Jerry Avorn, MD, 1 Robert J. Glynn,
More informationHealth Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial
Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationSAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014
Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationCustomized Patient Care through Patient Support Programs for Rare/Orphan Drugs. Sandra Anderson August 2015
Customized Patient Care through Patient Support Programs for Rare/Orphan Drugs Sandra Anderson August 2015 Why Orphan Drugs are Different Difficult to diagnose Population size Unique patient and caregiver
More informationProgrammes publics de médicaments de l Ontario. Bureau de l administratrice en chef et sous-ministre adjointe
Ministry of Health and Long-Term Care Ontario Public Drug Programs Office of the Executive Officer and Assistant Deputy Minister Hepburn Block, 9 th Floor 80 Grosvenor Street Queen s Park Toronto ON M7A
More informationUsing Medicare Hospitalization Information and the MedPAR. Beth Virnig, Ph.D. Associate Dean for Research and Professor University of Minnesota
Using Medicare Hospitalization Information and the MedPAR Beth Virnig, Ph.D. Associate Dean for Research and Professor University of Minnesota MedPAR Medicare Provider Analysis and Review Includes information
More informationMarina Richardson, M.Sc. Deb Willems, BSc.PT David Ure, OT Robert Teasell, MD FRCPC
Assessing the Impact of Southwestern Ontario s Community Stroke Rehabilitation Teams: An Economic Analysis Presenters: Laura Allen, M.Sc. (cand.) Matthew Meyer, Ph.D (cand.) Marina Richardson, M.Sc. Deb
More informationPresenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands
Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting
More informationSummary Evaluation of the Medicare Lifestyle Modification Program Demonstration and the Medicare Cardiac Rehabilitation Benefit
The Centers for Medicare & Medicaid Services' Office of Research, Development, and Information (ORDI) strives to make information available to all. Nevertheless, portions of our files including charts,
More informationStewart B. Harris MD, MPH, FCFP, FACPM. 2 nd Annual Congress of the Global Diabetes Alliance (GDA) October 26-29, 2010 Cairo, Egypt
SUMMIT SESSION: The challenges and applications of diabetes registries and electronic medical records (EMR's) in improving clinical care for patients with diabetes; a global perspective 2 nd Annual Congress
More informationThe Health of Canada s Health Care System M D, M H A, C C F P, F C F P
The Health of Canada s Health Care System D r. Stewart Kennedy, M D, M H A, C C F P, F C F P E x ecutive Vice President, M edicine and Academics T hunder Bay Regional Health S c i ences Centre Biographical
More informationReport of the Information & Privacy Commissioner/Ontario. Review of the Canadian Institute for Health Information:
Information and Privacy Commissioner of Ontario Report of the Information & Privacy Commissioner/Ontario Review of the Canadian Institute for Health Information: A Prescribed Entity under the Personal
More informationLEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
More informationA Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III
A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France
More informationThe below tables outline the types of health care services as well as delivery settings:
Assuring Quality Health Care Delivery in Asia Introduction Guk-Hee Suh, PhD, MD, 2014-2016 Chair, ISPOR Asia Consortium Health Service Providers (Clinicians) Committee, and Professor of Psychiatry, Hallym
More informationCancer Drug Reimbursement within the Context of Clinical Trials. (Draft for consultation purposes) Version 8.0
Cancer Drug Reimbursement within the Context of Clinical Trials (Draft for consultation purposes) Version 8.0 May 17, 2013 Introduction Clinical and cost-effectiveness factors have led most public payers
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More information2003 FIRST MINISTERS ACCORD
2003 FIRST MINISTERS ACCORD ON HEALTH CARE RENEWAL 1 In September 2000, First Ministers agreed on a vision, principles and action plan for health system renewal. Building from this agreement, all governments
More informationOPTIMIZING THE USE OF YOUR ELECTRONIC HEALTH RECORD. A collaborative training offered by Highmark and the Pittsburgh Regional Health Initiative
OPTIMIZING THE USE OF YOUR ELECTRONIC HEALTH RECORD A collaborative training offered by Highmark and the Pittsburgh Regional Health Initiative Introductions Disclosures Successful completion of training
More informationPlatelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.
Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel Kiyuk Chang, M.D., Ph.D. Cardiovascular Center & Cardiology Division Seoul St. Mary s Hospital The Catholic University
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent
More informationThe Ontario Cancer Research Ethics Board Overview
The Ontario Cancer Research Ethics Board Overview Research Ethics Research ethics review is vital to the advancement of ethically sound research. Before individuals can be enrolled in a research study,
More informationA Year in Review: CIHI s 2013 2014 Annual Privacy Report
A Year in Review: CIHI s 2013 2014 Annual Privacy Report Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and integrated
More informationSmoking Cessation Program
Guide to Pharmacist Health Coaching Smoking Cessation Program Smoking is the leading cause of preventable death in Canada and a significant risk factor for many chronic non-communicable diseases including
More informationPrivacy Policy on the Collection, Use, Disclosure and Retention of Personal Health Information and De-Identified Data, 2010
pic pic Privacy Policy on the Collection, Use, Disclosure and Retention of Personal Health Information and De-Identified Data, 2010 Updated March 2013 Our Vision Better data. Better decisions. Healthier
More informationUtilization Review Cardiac Rehabilitation Services: Underutilized
Utilization Review Cardiac Rehabilitation Services: Underutilized William J. Gill, MD Krannert Institute of Cardiology Indiana University School of Medicine Indianapolis, Indiana What is Cardiac Rehab?
More informationAntonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
More informationPharmaCare is BC s public drug insurance program that assists BC residents in paying for eligible prescription drugs and designated medical supplies.
PHARMANET AND PHARMACARE DATA DICTIONARY Date Range: September 1, 1995 to present date, data is provided by calendar year Data Source: BC Ministry of Health Description The PharmaNet system is an online,
More informationGuide to Chronic Disease Management and Prevention
Family Health Teams Advancing Primary Health Care Guide to Chronic Disease Management and Prevention September 27, 2005 Table of Contents 3 Introduction 3 Purpose 4 What is Chronic Disease Management
More informationMajestic Trial 12 Month Results
Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.
More informationCANADA: A WORLD LEADING LOCATION TO CONDUCT CLINICAL TRIALS
CANADA: A WORLD LEADING LOCATION TO CONDUCT CLINICAL TRIALS Canada is a world leading location for pharmaceutical and medical device companies to conduct their clinical trials. Both publicly available
More informationNova Scotia Pharmacare Programs
Nova Scotia Pharmacare Programs The Nova Scotia Family Pharmacare Program Effective December 2012 The information in this booklet is subject to change and does not replace the Health Services and Insurance
More informationElectronic Health Records
Electronic Health Records AN OVERVIEW OF FEDERAL AND PROVINCIAL AUDIT REPORTS APRIL 2010 Office of the Auditor General of Canada Bureau du vérificateur général du Canada PARTICIPATING LEGISLATIVE AUDIT
More informationPrivacy and Security Framework, February 2010
Privacy and Security Framework, February 2010 Updated April 2014 Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and
More informationFunding Privacy Commissioner of Canada: Secondary use of data from the EHR current governance challenges & potential approaches
Don Willison, Sc.D. Senior Scientist, Ontario Agency for Health Protection and Promotion Associate Professor, Part time, Clinical Epidemiology & Biostatistics, McMaster University don.willision@oahpp.ca
More informationStent for Life Initiative How can we improve system delay and patients delay in STEMI
Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration
More informationCPCA California Primary Care Association
CPCA California Primary Care Association Accountable Care Organizations: Next Generation Systems for Community Health Centers? CPCA Annual Conference Sacramento, California October 10, 2014 Larry Garcia,
More information06 Validation of risk prediction model
HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via
More informationSubmission to the Standing Committee on Finance and Economic Affairs - 2015 Pre-Budget Consultations -
Submission to the Standing Committee on Finance and Economic Affairs - 2015 Pre-Budget Consultations - Presented by: James Swan, MD, F.R.C.P.(C) F.A.C.C. President Ontario Association of Cardiologists
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationSubmitted Electronically to AdvanceNotice2016@cms.hhs.gov
March 6, 2015 Marilyn Tavenner, RN, BSN, MHA Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services 200 Independence Avenue, SW Washington, D.C. 20201 Submitted
More informationIntracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting
More informationPhysicians Views on a Publicly Funded Prescription Drug Program for Ontario Seniors
Physicians Views on a Publicly Funded Prescription Drug Program for Ontario Seniors Rima Karam, MHSc (candidate) Supervisory Committee: Dr. Brenda Gamble. PhD Dr. Otto Sanchez MD, PhD Dr. Edward Osborne
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationHealth: Electronic Health Records
Performance Audits 2 Electronic Health Records Summary Nova Scotia is working towards the development of a provincial electronic health record system known as SHARE. The province is participating in and
More informationCanadian Provincial and Territorial Early Hearing Detection and Intervention. (EHDI) Programs: PROGRESS REPORT
Canadian Provincial and Territorial Early Hearing Detection and Intervention (EHDI) Programs: PROGRESS REPORT www.sac-oac.ca www.canadianaudiology.ca 1 EHDI PROGRESS REPORT This progress report represents
More informationMINISTRY OF HEALTH AND LONG-TERM CARE
THE ESTIMATES, 1 The Ministry provides for a health system that promotes wellness and improves health outcomes through accessible, integrated and quality services at every stage of life for all Ontarians.
More informationThe Use of MHCC Data to Support Monitoring of the New Medicare Waiver
The Use of MHCC Data to Support Monitoring of the New Medicare Waiver A Presentation before the HSCRC Data and Infrastructure Workgroup March 4, 2014 Linda Bartnyska & Theressa Lee Presentation Overview
More informationThe Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model
The Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model WK Evans, M Wolfson, WM Flanagan, J Shin, FF Liu JR Goffin, K Asakawa, N Mittmann, L Fairclough
More informationNatalia Olchanski, MS, Paige Lin, PhD, Aaron Winn, MPP. Center for Evaluation of Value and Risk in Health, Tufts Medical Center.
ISPOR 2013, New Orleans, LA Using EMR data for conducting retrospective studies: Opportunities and Pitfalls Natalia Olchanski, MS, Paige Lin, PhD, Aaron Winn, MPP Center for Evaluation of Value and Risk
More informationA Guide to Ontario Legislation Covering the Release of Students
A Guide to Ontario Legislation Covering the Release of Students Personal Information Revised: June 2011 Ann Cavoukian, Ph.D. Information and Privacy Commissioner, Ontario, Canada Commissioner, Ontario,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationComparative Effectiveness Research and Medical Devices in the Healthcare Environment
Comparative Effectiveness Research and Medical Devices in the Healthcare Environment Jessica Jalbert, PhD LA-SER Analytica/Weill Cornell Medical College Mary E Ritchey, PhD Proctor & Gamble Outline Disclaimer:
More informationHITECH Act Update: An Overview of the Medicare and Medicaid EHR Incentive Programs Regulations
HITECH Act Update: An Overview of the Medicare and Medicaid EHR Incentive Programs Regulations The Health Information Technology for Economic and Clinical Health Act (HITECH Act) was enacted as part of
More informationResponse to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers
Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Brief submitted by The New Brunswick Nurses Union April 2012 Background The New Brunswick
More informationWill a pan-canadian approach to drug purchasing save the provinces money?
Will a pan-canadian approach to drug purchasing save the provinces money? combining the purchasing power of the public drug programs would help provinces and territories achieve economies of scale and
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationIs There A LIfe for DES after discontinuation of Clopidogrel
Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin:
More informationBenefit Design and ACOs: How Will Private Employers and Health Plans Proceed?
Benefit Design and ACOs: How Will Private Employers and Health Plans Proceed? Accountable Care Organizations: Implications for Consumers October 14, 2010 Washington, DC Sam Nussbaum, M.D. Executive Vice
More informationReimbursement for Medical Products: Ensuring Marketplace
Reimbursement for Medical Products: Ensuring Marketplace Success by Securing Coverage and Payment Christopher J. Panarites, Ph.D. Director, Endovascular Products Health Economics and Outcomes Research
More informationArthritis Foundation Position Statement on Biosimilar Substitution
Arthritis Foundation Position Statement on Biosimilar Substitution The Affordable Care Act creates a regulatory pathway for the approval of a new generation of biologic medications called biosimilars.
More informationHow To Ensure Health Information Is Protected
pic pic CIHI Submission: 2011 Prescribed Entity Review October 2011 Who We Are Established in 1994, CIHI is an independent, not-for-profit corporation that provides essential information on Canada s health
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationPrimary Health Care Voluntary Reporting System Privacy Impact Assessment, January 2013
Primary Health Care Voluntary Reporting System Privacy Impact Assessment, January 2013 Factors Infl uencing Health Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the
More informationCOMPLYING WITH THE PERSONAL HEALTH INFORMATION ACT
COMPLYING WITH THE PERSONAL HEALTH INFORMATION ACT The Personal Health Information Act, S.N.S. 2010, c.41 (referred to as PHIA or the Act ) was passed by the Nova Scotia government on December 10, 2010.
More informationMEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE
DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:
More informationPublic reporting improves healthcare. Jack Chen MBBS PhD MBA
Public reporting improves healthcare Jack Chen MBBS PhD MBA October 2010 BUREAU OF HEALTH INFORMATION PO Box 1770 Chatswood NSW 2057 Australia Telephone: +61 2 8644 2100 www.bhi.nsw.gov.au This work is
More informationHealth Care Systems: An International Comparison. Strategic Policy and Research Intergovernmental Affairs May 2001
Health Care Systems: An International Comparison Strategic Policy and Research Intergovernmental Affairs May 21 1 Most industrialized countries have established hybrid systems in which the public sector,
More informationTELEHEALTH CLINICAL GUIDELINES
TELEHEALTH CLINICAL GUIDELINES Table of Contents Table of Contents... 1 1. Introduction... 2 1.1. Purpose... 2 1.1. Background... 2 2. Definitions... 4 3. Guidelines... 5 3.1. Telehealth and Clinical Practice...
More informationIC 3 : Improving Continuous Cardiac Care Quality Improvement in Practice
IC 3 : Improving Continuous Cardiac Care Quality Improvement in Practice Presenter Disclosure Information Paul Chan, MD FINANCIAL DISCLOSURE: None FUNDING FOR THE IC3 PROGRAM: Bristol-Myers Squibb / Sanofi
More informationHEALTH CARE DATA IN QATAR
HEALTH CARE DATA IN QATAR Daoud Al-Badriyeh, PhD President, ISPOR Qatar Chapter and Assistant Professor of Pharmacoeconomics College of Pharmacy, Qatar University Doha, Qatar Health Care Data The problem:
More informationJUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular
More informationOverview Of Cardiac Rehabilitation Programs In Malaysia Updates & Innovations
Overview Of Cardiac Rehabilitation Programs In Malaysia Updates & Innovations Aizai Azan Rahim Cardiology Department National Heart Institute Topics Historical Perspective Of Cardiac Rehabilitation CPG
More informationOntario Patient Rostering. Mary Fleming Director, Primary Health Care Ontario Ministry of Health and Long-Term Care
Ontario Patient Rostering Mary Fleming Director, Primary Health Care Ontario Ministry of Health and Long-Term Care 1 the essence of primary care reform Patient enrolment is a key element of the models
More informationOur Vision Better data. Better decisions. Healthier Canadians.
Population Risk Adjustment Grouping Project Privacy Impact Assessment, January 2015 Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of
More informationPooled RESOLUTE Clinical Program
The Relationship Between Short and Long-term Antiplatelet Therapy Use and Stent Thrombosis Following Percutaneous Coronary Intervention With the Resolute Zotarolimus-eluting Stent Pooled RESOLUTE Clinical
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationLifetime Maximum Applies to all expenses; Part A and Part B expenses cross accumulate to the lifetime maximum
This is a summary of benefits for your Joint Trusteed Health and Welfare Medicare Supplement (Part A & B) plan. Medicare Part D prescription drug plan deductibles, out-of-pocket maximums, copays and annual
More informationINSTITUTE FOR SAFE MEDICATION PRACTICES CANADA
INSTITUTE FOR SAFE MEDICATION PRACTICES CANADA PRIVACY IMPACT ASSESSMENT (PIA) ON ANALYZE-ERR AND CURRENT DATA HANDLING OPERATIONS VERSION 3.0-2 JULY 11, 2005 PREPARED IN CONJUNCTION WITH: ISMP Canada
More informationProtection For Your Mortgage
Protection For Your Mortgage Protect What s Important Product Guide and Certificate of Insurance 592258(1115) Protection For Your Mortgage Protect What s Important Product Guide and Certificate of Insurance
More informationQuality Improvement Plan (QIP) Narrative for Health Care Organizations in Ontario 3/31/2015
Quality Improvement Plan (QIP) Narrative for Health Care Organizations in Ontario 3/31/2015 This document is intended to provide health care organizations in Ontario with guidance as to how they can develop
More informationThe Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion
November 2013 Edition Vol. 7, Issue 10 The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion By Gordon Gochenauer, Director, Oncology Commercial Strategies,
More informationGuide to Health Promotion and Disease Prevention
Family Health Teams Advancing Primary Health Care Guide to Health Promotion and Disease Prevention January 16, 2006 Table of Contents 3 Introduction 3 Purpose 3 Background 4 Developing Health Promotion
More informationUnitedHealth Premium Designation Program. Driving informed choices and quality, efficient care
UnitedHealth Premium Designation Program Driving informed choices and quality, efficient care Today s health care system is fraught with wide variation in medical practices that often result in inconsistent
More informationCalifornia Health and Safety Code, Section 1256.01
California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program
More informationPrivacy Update Recent Updates in Privacy Law
Privacy Update Recent Updates in Privacy Law Kathryn Frelick DISCLAIMER This Coffee Talk presentation is provided as an information service and is not meant to be taken as legal opinion or advice. Please
More informationStroke Rehabilitation Triage Severe Strokes
The London Stroke Rehab Data Base Project Robert Teasell MD FRCPC Professor and Chair-Chief Department of Phys Med Rehab London Ontario Retrospective Data Bases In stroke rehab limited funding for clinical
More informationResearch Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources
Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources James Floyd, MD, MS Sep 17, 2015 UW Hospital Medicine Faculty Development Program Objectives Become more
More informationDevelopment and Testing of a Decision Support Tool for Healthcare Performance Measurement
Development and Testing of a Decision Support Tool for Healthcare Performance Measurement March 2001 Geoffrey Anderson MD, PhD Adalsteinn Brown Funding Provided by: Canadian Health Services Research Foundation
More informationUsing Health Information Technology to Improve Quality of Care: Clinical Decision Support
Using Health Information Technology to Improve Quality of Care: Clinical Decision Support Vince Fonseca, MD, MPH Director of Medical Informatics Intellica Corporation Objectives Describe the 5 health priorities
More information